Scott Mestemaker

Scott Mestemaker has a diverse work experience spanning over several industries. Their most recent role is as the AVP of Marketing at Stemline Therapeutics, a position they have held since May 2022. Scott is also an Advisor at 4M Therapeutics Inc., a start-up biotechnology company specializing in potential medicines for bipolar disorder and other neuropsychiatric conditions.

Prior to these roles, Scott held the position of Executive Director of Marketing at Gilead Sciences (formerly Immunomedics) from November 2020 to April 2022. In this role, they led the strategy development and promotion for the launches of Trodelvy, a new Antibody Drug Conjugate in the breast cancer and urothelial bladder cancer markets.

Scott's previous experiences include being the Executive Director of Marketing at Immunomedics from November 2019 to November 2020, the National Sales Director - Oncology and Marketing Director - Oncology at Lexicon Pharmaceuticals, Inc. from November 2014 to November 2019, and an Independent Consultant from June 2014 to November 2014, where they worked with Phoenix Marketing Solutions and conducted commercial assessments and market opportunities for medical devices.

Prior to these roles, Scott worked at Bristol-Myers Squibb as the Director of Marketing from July 2013 to May 2014 and in various marketing roles in the Oncology and Breast Cancer divisions from March 2011 to June 2013. Scott also has a tenure at Merck, where they held roles such as Global Sr Marketing Manager, Business Manager, Manager Marketing Analysis, Trainer and Professional Development Manager, and Sales Representative in various departments from 1997 to 2011.

Before their career in the pharmaceutical industry, Scott worked as an Ecologist/Biologist at the National Marine Fisheries Service, the US Department of Energy, and the National Peace Corps Association from June 1994 to October 1997.

Scott Mestemaker has a Bachelor's degree in Biology, with a focus on Pre-Med, from the University of Dayton. Scott also attended the Colorado School of Mines where they studied Environmental Sciences. In 2004, they completed a short-term program in Finance at the Wharton Executive Education.